Ellie Leick

Gilberto De Lima Lopes, MD, discusses the impact of COVID-19 on his practice and how he is coping with the changes caused by the pandemic.

Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.

Melinda L. Telli, MD, discusses the role of PARP inhibition in the treatment of patients with breast cancer who harbor the BRCA mutations and ongoing research efforts seeking to expand their use beyond this setting.

Omid Hamid, MD, discusses emerging treatment approaches, the role of surgery, and ongoing research efforts in melanoma.

Shaji Kumar, MD, discusses the role of stem cell transplant in multiple myeloma, different techniques for stem cell mobilization, and remaining challenges faced with this modality.

Jorge E. Cortes, MD, discusses managing treatment toxicities to optimize therapeutic outcomes in patients with CML and MPNs.

Shilpa Gupta, MD, discusses the modifications made to patient care in light of the COVID-19 pandemic, the hurdles faced with clinical trials during this time, and some of the ways in which her institution is facing the virus-related challenges head-on.

Suresh S. Ramalingam, MD, FASCO, discusses the adjustments being made in cancer care due to the rapid spread of COVID-19 and treatments under development.

Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.

Rana R. McKay, MD, discusses the evolving role of cabozantinib in the renal cell carcinoma treatment paradigm and the research being done examining novel combinations.

Derek Thomas, MD, discusses his experience as a community oncologist and some challenges faced in practice.

Enrique Soto Pérez de Celis, MD, MSc, discusses some of the challenges of treating geriatric patients with breast cancer, emerging treatment options for this patient population, and recommendations for treating older patients.

Jerald P. Radich, MD, discusses the growing importance of MRD assessment in the treatment paradigm for patients with hematologic malignancies.

Hossein Borghaei, DO, MS, discusses the impact of COVID-19 on clinical practice and projected how the virus will change practice for the better in the long term.

Nathan Pennell, MD, PhD, offers strategies regarding molecular testing in patients with lung cancer and how to address treatment if patients are symptomatic and molecular testing results are unavailable.

Carlos R. Bachier, MD, discusses the use of CAR T-cell therapy in the outpatient setting. He also shared insight on the evolving paradigm of graft-versus-host disease.

Tania Jain, MBBS, discusses blood count recovery in patients with hematology malignancies who receive CAR T-cell therapy.

Jason D. Wright, MD, discusses the findings of this trial and how practice can shift to decrease the gap between African-American and white patients with endometrial cancer.

Charu Aggarwal, MD, MPH, discusses the design and findings of an analysis examining the role of TMB as a predictive biomarker for pembrolizumab-based therapy in NSCLC.

Sagar Lonial, MD, FACP, discusses the encouraging activity with the BCMA-targeted agent belantamab mafodotin in multiple myeloma.

David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.

Terence T. Sio, MD, MS, discusses the utility of proton therapy in lung cancer.

Che-Kai Tsao, MD, discusses the current unmet needs in adjuvant therapy for patients with renal cell carcinoma and how current research is addressing such challenges.

Anastasios Dimou, MD, discusses available and emerging treatment options and approaches for patients with oncogenic-driven lung cancer.

Neeta Somaiah, MD, discusses ongoing research in the field of sarcoma.

Jonathan C. Trent, MD, PhD, discusses recent advances and ongoing research in the field of soft tissue sarcoma.

Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR, discusses the findings of the retrospective analysis of pulmonary hypertension in patients with myelofibrosis and their impact on clinical practice.

Petros Grivas MD, PhD, discusses biomarker-driven and combination research in metastatic castration-resistant prostate cancer.

Matthew H.G. Katz, MD, FACS, discusses data with neoadjuvant therapy and ongoing research in pancreatic cancer.

Mohammad Maher Abdul-Hay, MD, discusses current standards for the treatment of patients with acute lymphocytic leukemia.